0001179110-20-011838.txt : 20201211 0001179110-20-011838.hdr.sgml : 20201211 20201211180842 ACCESSION NUMBER: 0001179110-20-011838 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201209 FILED AS OF DATE: 20201211 DATE AS OF CHANGE: 20201211 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MCLAUGHLIN KEVIN F CENTRAL INDEX KEY: 0001214938 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36065 FILM NUMBER: 201384628 MAIL ADDRESS: STREET 1: C/O ACCELERON PHARMA INC. STREET 2: 128 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ACCELERON PHARMA INC CENTRAL INDEX KEY: 0001280600 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 128 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-649-9200 MAIL ADDRESS: STREET 1: 128 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 edgar.xml FORM 4 - X0306 4 2020-12-09 0 0001280600 ACCELERON PHARMA INC XLRN 0001214938 MCLAUGHLIN KEVIN F 128 SIDNEY STREET CAMBRIDGE MA 02139 0 1 0 0 SVP, CFO and Treasurer Common Stock 2020-12-09 4 M 0 548 41.20 A 11764 D Common Stock 2020-12-09 4 M 0 400 27.97 A 12164 D Common Stock 2020-12-09 4 M 0 1051 30.17 A 13215 D Common Stock 2020-12-09 4 M 0 1873 40.61 A 15088 D Common Stock 2020-12-09 4 S 0 3872 125.03 D 11216 D Common Stock 2020-12-10 4 M 0 100 41.20 A 11316 D Common Stock 2020-12-10 4 M 0 200 27.97 A 11516 D Common Stock 2020-12-10 4 M 0 100 30.17 A 11616 D Common Stock 2020-12-10 4 M 0 100 40.61 A 11716 D Common Stock 2020-12-10 4 S 0 500 125.12 D 11216 D Common Stock 2020-12-11 4 M 0 3100 41.20 A 14316 D Common Stock 2020-12-11 4 S 0 3100 125.00 D 11216 D Option to Purchase Common Stock 41.20 2020-12-09 4 M 0 548 0 D 2025-01-08 Common Stock 548 10452 D Option to Purchase Common Stock 27.97 2020-12-09 4 M 0 400 0 D 2026-03-03 Common Stock 400 7900 D Option to Purchase Common Stock 30.17 2020-12-09 4 M 0 1051 0 D 2027-03-02 Common Stock 1051 30249 D Option to Purchase Common Stock 40.61 2020-12-09 4 M 0 1873 0 D 2028-03-01 Common Stock 1873 28952 D Option to Purchase Common Stock 41.20 2020-12-10 4 M 0 100 0 D 2025-01-08 Common Stock 100 10352 D Option to Purchase Common Stock 27.97 2020-12-10 4 M 0 200 0 D 2026-03-03 Common Stock 200 7700 D Option to Purchase Common Stock 30.17 2020-12-10 4 M 0 100 0 D 2027-03-02 Common Stock 100 30149 D Option to Purchase Common Stock 40.61 2020-12-10 4 M 0 100 0 D 2028-03-01 Common Stock 100 28852 D Option to Purchase Common Stock 41.20 2020-12-11 4 M 0 3100 0 D 2025-01-08 Common Stock 3100 7252 D The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.00 to $125.27 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. The shares of common stock underlying this stock option award vested in equal quarterly installments over the four years after the grant. The shares of common stock underlying this stock option award vested in equal quarterly installments over the four years after January 1, 2016. The shares of common stock underlying this stock option award vest in equal quarterly installments over the four years after January 1, 2017. The shares of common stock underlying this stock option award vest in equal quarterly installments over the four years after January 1, 2018. /s/ Adam M. Veness, as attorney-in-fact for Kevin F. McLaughlin 2020-12-11